

=> d hitstr 1

L12 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN


IT 291778-80-8P 291778-97-7P 291779-23-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of proline-contg. peptides, intermediates thereof, and elastase inhibitors)

RN 291778-80-8 CAPLUS

CN L-Prolinamide, N-[[3-(carboxymethyl)-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291778-97-7 CAPLUS

CN L-Prolinamide, N-[[4-(carboxymethyl)-2,3-dioxo-1-piperazinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291779-23-2 CAPLUS

CN L-Prolinamide, N-[[4-(carboxymethyl)-1-piperazinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 291778-81-9P 291778-98-8P 291779-24-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of proline-contg. peptides, intermediates thereof, and elastase inhibitors)

RN 291778-81-9 CAPLUS

CN L-Prolinamide, N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291778-98-8 CAPLUS

CN L-Prolinamide, N-[[4-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2,3-dioxo-1-piperazinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291779-24-3 CAPLUS

CN L-Prolinamide, N-[[4-[2-(1,1-dimethylethoxy)-2-oxoethyl]-1-piperazinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib 1

L12 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2000:628158 CAPLUS  
 DN 133:223051  
 TI Preparation of proline-containing peptides, intermediates thereof, and elastase inhibitors  
 IN Sato, Fuminori; Inoue, Yasunao; Omodani, Tomoki; Shiratake, Ryotaro; Honda, Seiji; Komiya, Masanobu; Takemura, Tadashi  
 PA Dainippon Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 65 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000052032	A1	20000908	WO 2000-JP1022	20000223 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2000256396	A2	20000919	JP 1999-56052	19990303 <--
	EP 1157998	A1	20011128	EP 2000-905282	20000223
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008600	A	20011226	BR 2000-8600	20000223
	AU 758739	B2	20030327	AU 2000-26902	20000223 <--
	AU 2000026902	A5	20000921		
	NZ 513594	A	20030429	NZ 2000-513594	20000223
	ZA 2001006514	A	20020510	ZA 2001-6514	20010808
PRAI	JP 1999-56052	A	19990303		
	WO 2000-JP1022	W	20000223		

17/09/200314:26Print selected from Online session

OS MARPAT 133:223051

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.84	534.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.51	-33.20

FILE 'STNGUIDE' ENTERED AT 14:11:44 ON 17 SEP 2003  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 12, 2003 (20030912/UP).

=> d hitstr 2

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN


IT **274918-59-1 274918-61-5 274918-62-6**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. of peptide-based .alpha.-keto amides, .alpha.-keto esters, and .alpha.-diketones as HCV NS3 protease inhibitors)

RN 274918-59-1 CAPLUS

CN L-Prolinamide, L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[(ethylamino)oxoacetyl]-3-butenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274918-61-5 CAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]-3-butenyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274918-62-6 CAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-ethyl-2,3-dioxo-3-(2-propenylamino)propyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 274918-50-2P 274918-55-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of peptide-based .alpha.-keto amides, .alpha.-keto esters, and .alpha.-diketones as HCV NS3 protease inhibitors)

RN 274918-50-2 CAPLUS

CN L-Prolinamide, L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]-3-butenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274918-55-7 CAPLUS

CN L-Prolinamide, L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-ethyl-2,3-dioxo-3-(2-propenylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib 2

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 2000:269109 CAPLUS  
DN 133:43798  
TI .alpha.-Keto amides, .alpha.-keto esters, and .alpha.-diketones as HCV NS3  
protease inhibitors  
AU Han, Wei; Hu, Zilun; Jiang, Xiangjun; Decicco, Carl P.  
CS Department of Chemical and Physical Sciences, DuPont Pharmaceuticals  
Company, Wilmington, DE, 19880, USA  
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(8), 711-713  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
OS CASREACT 133:43798  
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib 3

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1999:571832 CAPLUS  
DN 131:170645  
TI Preparation of acylated enol derivatives of .alpha.-ketoesters and  
.alpha.-ketoamides as neutrophil-associated inflammation inhibitors  
IN Peet, Norton P.; Burkhardt, Joseph P.; Mehdi, Shujaath  
PA Hoechst Marion Roussel, Inc., USA  
SO U.S., 25 pp., Cont. of U.S. Ser. No. 754,081, abandoned.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5948886	A	19990907	US 1997-978096	19971125 <--
	US 6172044	B1	20010109	US 1999-303965	19990503
PRAI	US 1996-754081	B1	19961120		
	US 1996-31083P	P	19961201		
	US 1997-978096	A1	19971125		

OS MARPAT 131:170645  
RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib 4

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1999:126925 CAPLUS  
 DN 130:168666  
 TI Preparation of peptide analogs as hepatitis C inhibitors  
 IN Llinas-Brunet, Montse; Bailey, Murray Douglas; Halmos, Teddy; Poupart, Marc-Andre; Tsantrizos, Youla  
 PA Boehringer Ingelheim (Canada) Ltd., Can.  
 SO PCT Int. Appl., 122 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9907734	A2	19990218	WO 1998-CA764	19980810 <--
	WO 9907734	A3	19990520		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9888466	A1	19990301	AU 1998-88466	19980810 <--
	AU 757072	B2	20030130		
	EP 1012180	A2	20000628	EP 1998-939997	19980810 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	US 6143715	A	20001107	US 1998-131433	19980810 <--
	JP 2001512744	T2	20010828	JP 2000-506236	19980810
	NZ 503263	A	20021025	NZ 1998-503263	19980810
	MX 200001491	A	20001110	MX 2000-1491	20000211 <--
PRAI	US 1997-55247P	P	19970811		
	WO 1998-CA764	W	19980810		
OS	MARPAT 130:168666				


=> d hitstr 3

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
 IT **192193-38-7P 192193-39-8P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of ketoester and ketoamide acylated enol derivs. as neutrophil-assocd. inflammation inhibitors)  
 RN 192193-38-7 CAPLUS  
 CN L-Prolinamide, N-[4-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]benzoyl]-L-valyl-N-[3-amino-1-(1-methylethyl)-2,3-dioxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 192193-39-8 CAPLUS

CN L-Prolinamide, N-[4-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]benzoyl]-L-valyl-N-[1-(1-methylethyl)-2,3-dioxo-3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NHPh

=> d hitstr 4

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN

IT 220440-36-8P 220440-42-6P 220440-45-9P  
220440-48-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of peptide analogs as hepatitis C inhibitors)

RN 220440-36-8 CAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-aspartyl-D-.alpha.-glutamyl-L-isoleucyl-

L-valyl-N-[1-[oxo[(phenylmethyl)amino]acetyl]butyl]-4-(phenylmethoxy)-,  
(4R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220440-42-6 CAPLUS

CN L-Prolinamide, N-acetyl-2-cyclohexylglycyl-L-valyl-N-[1-  
[oxo[(phenylmethyl)amino]acetyl]butyl]-4-(phenylmethoxy)-, (4R) - (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 220440-45-9 CAPLUS


CN L-Prolinamide, N-acetyl-L-.alpha.-aspartyl-D-.alpha.-glutamyl-L-isoleucyl-  
L-valyl-N-[1-[oxo[(phenylmethyl)amino]acetyl]butyl]- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.



RN 220440-48-2 CAPLUS  
 CN L-Prolinamide, N-acetyl-2-cyclohexylglycyl-L-valyl-N-[1-[oxo[(4-pyridinylmethyl)amino]acetyl]butyl]-4-(phenylmethoxy)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib 5  
 YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1998:709961 CAPLUS  
 DN 130:66781  
 TI Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease  
 AU Llinas-Brunet, Montse; Bailey, Murray; Ddziel, Robert; Fazal, Gulrez; Gorys, Vida; Goulet, Sylvie; Halmos, Ted; Maurice, Roger; Poirier, Martin; Poupart, Marc-Andre; Rancourt, Jean; Thibeault, Diane; Wernic, Dominik; Lamarre, Daniel  
 CS Bio-Mega Research Division, Boehringer Ingelheim (Canada) Ltd., Laval, H7S 2G5, Can.

SO Bioorganic & Medicinal Chemistry Letters (1998), 8(19),  
2719-2724  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib 6

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1998:268513 CAPLUS  
DN 128:321945  
TI Preparation of peptide analogs as inhibitors of serine proteases,  
particularly hepatitis C virus NS3 protease  
IN Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.;  
Bhisetti, Govinda Rao; Farmer, Luc J.  
PA Vertex Pharmaceuticals Inc., USA; Tung, Roger D.; Harbeson, Scott L.;  
Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc  
J.  
SO PCT Int. Appl., 128 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817679	A1	19980430	WO 1997-US18968	19971017 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9709327	A	19980511	ZA 1997-9327	19971017 <--
AU 9851477	A1	19980515	AU 1998-51477	19971017 <--
AU 719984	B2	20000518		
EP 932617	A1	19990804	EP 1997-946273	19971017 <--
EP 932617	B1	20020116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IN 183120	A	19990911	IN 1997-CA1951	19971017 <--
BR 9712544	A	19991019	BR 1997-12544	19971017 <--
CN 1238780	A	19991215	CN 1997-180151	19971017 <--
NZ 335276	A	20000929	NZ 1997-335276	19971017 <--
JP 2001502694	T2	20010227	JP 1998-519568	19971017
EP 1136498	A1	20010926	EP 2001-109433	19971017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AP 1019	A	20011016	AP 1999-1512	19971017
W: GH, KE, LS, MW, SD, SZ, UG, ZW				

AT 212037	E	20020215	AT 1997-946273	19971017
ES 2169880	T3	20020716	ES 1997-946273	19971017
EE 4023	B1	20030415	EE 1999-161	19971017
NO 9901832	A	19990617	NO 1999-1832	19990416 <--
US 6265380	B1	20010724	US 1999-293247	19990416
KR 2000049263	A	20000725	KR 1999-703372	19990417 <--
HK 1023779	A1	20020927	HK 2000-100690	20000203
US 2002032175	A1	20020314	US 2001-875390	20010606
US 6617309	B2	20030909		
PRAI US 1996-28290P	P	19961018		
EP 1997-946273	A3	19971017		
WO 1997-US18968	W	19971017		
US 1999-293247	A	19990416		
OS MARPAT 128:321945				

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 6

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN

IT **207001-60-3P 207001-61-4P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of peptide analogs as hepatitis C virus NS3 protease inhibitors)

RN 207001-60-3 CAPLUS

CN L-Prolinamide, N-(pyrazinylcarbonyl)-L-valyl-L-valyl-N-[(1S)-1-ethyl-2,3-dioxo-3-[(2-phenylethyl)amino]propyl]-4-(phenylmethoxy)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207001-61-4 CAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-valyl-L-valyl-N-[(1S)-1-ethyl-2,3-dioxo-3-[(2-phenylethyl)amino]propyl]-4-(phenylmethoxy)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib 7

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1997:636187 CAPLUS  
 DN 127:293640  
 TI Preparation of peptidyl .alpha.-ketoamide derivatives as inhibitors of  
 thrombosis  
 IN Abelman, Matthew M.; Pearson, Daniel A.; Vlasuk, George P.; Webb, Thomas  
 R.  
 PA Corvas International, Inc., USA  
 SO U.S., 116 pp., Cont.-in-part of U.S. Ser. No. 37,574.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5670479	A	19970923	US 1994-218329	19940325 <--
	US 5656600	A	19970812	US 1993-37574	19930325 <--
	CA 2158989	AA	19940929	CA 1994-2158989	19940325 <--
PRAI	US 1993-37574		19930325		
OS	MARPAT 127:293640				

=> d hitstr 7

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
 IT 166247-65-0P 166247-66-1P 166247-67-2P


166247-68-3P 166247-69-4P 166247-70-7P  
 166247-71-8P 166247-72-9P 166247-75-2P  
 166247-76-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (peptidyl ketoamide derivs. as inhibitors of thrombosis)


RN 166247-65-0 CAPLUS

CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginyglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 1-C







PAGE 2-A



PAGE 2-B



PAGE 2-C




RN 166247-66-1 CAPLUS


CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginyglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 166247-67-2 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







RN 166247-68-3 CAPLUS

CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B



PAGE 1-C




RN 166247-69-4 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

—CH(Pr-n)<sub>2</sub>

RN 166247-70-7 CAPLUS

CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-D


—CH(Pr-n)<sub>2</sub>

RN 166247-71-8 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





PAGE 1-C



PAGE 1-D


$$-\text{CH}(\text{Pr-n})_2$$

RN 166247-72-9 CAPLUS


CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D


—CH(Pr-n)<sub>2</sub>

RN 166247-75-2 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginyglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 166247-76-3 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

— OMe

=> d bib 8

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1997:491631 CAPLUS  
 DN 127:95620  
 TI Preparation of acylated enol derivatives of .alpha.-ketoesters and  
 .alpha.-ketoamides as neutrophil-associated inflammation inhibitors  
 IN Peet, Norton P.; Burkhardt, Joseph P.; Mehdi, Shujaath  
 PA Hoechst Marion Roussel, Inc., USA  
 SO PCT Int. Appl., 81 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9720856	A1	19970612	WO 1996-US17752	19961104 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2239159	AA	19970612	CA 1996-2239159	19961104 <--
CA 2239159	C	20020910		

AU 9676697	A1	19970627	AU 1996-76697	19961104 <--
AU 705819	B2	19990603		
EP 863915	A1	19980916	EP 1996-939555	19961104 <--
EP 863915	B1	20000202		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1203602	A	19981230	CN 1996-198733	19961104 <--
AT 189457	E	20000215	AT 1996-939555	19961104 <--
JP 2000502073	T2	20000222	JP 1997-521265	19961104 <--
ES 2144788	T3	20000616	ES 1996-939555	19961104 <--
ZA 9609889	A	19970617	ZA 1996-9889	19961125 <--
TW 419482	B	20010121	TW 1996-85114600	19961126
NO 9802467	A	19980803	NO 1998-2467	19980529 <--
PRAI US 1995-566196	A	19951201		
WO 1996-US17752	W	19961104		
OS MARPAT 127:95620				

=> d hitstr 8

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN

IT **192193-38-7P 192193-39-8P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of ketoester and ketoamide acylated enol derivs. as neutrophil-assocd. inflammation inhibitors)

RN 192193-38-7 CAPLUS

CN L-Prolinamide, N-[4-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]benzoyl]-L-valyl-N-[3-amino-1-(1-methylethyl)-2,3-dioxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192193-39-8 CAPLUS

CN L-Prolinamide, N-[4-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]benzoyl]-L-valyl-N-[1-(1-methylethyl)-2,3-dioxo-3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NHPH

=&gt; d bib 9

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1997:102091 CAPLUS  
 DN 126:199831  
 TI N-sulfonylarginine keto-amide compounds with antithrombotic activity  
 IN Webb, Thomas R.; Miller, Todd A.; Vlasuk, George P.; Abelman, Matthew M.  
 PA Corvas International, Inc., USA  
 SO U.S., 76 pp., Cont.-in-part of U.S. 5,371,072.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5597804	A	19970128	US 1993-139300	19931018 <--
	US 5371072	A	19941206	US 1992-962301	19921016 <--
	AT 178044	E	19990415	AT 1993-924369	19931018 <--
	US 5869454	A	19990209	US 1995-462899	19950605 <--
PRAI	US 1992-962301		19921016		
	US 1993-139300		19931018		
OS	MARPAT 126:199831				

=&gt; d hitstr

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:n

=&gt; d hitstr 9

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN

IT 159945-69-4P 159945-71-8P 159945-75-2P

159945-78-5P 159945-82-1P 159946-33-5P

187740-90-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate in prepn. of antithrombotic sulfonylarginine-contg. keto amide peptides)

RN 159945-69-4 CAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-N-[4-[[imino(nitroamino)methyl]amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159945-71-8 CAPLUS

CN L-Prolinamide, N-(4-methyl-1-oxopentyl)-L-.alpha.-aspartyl-N-[4-[[imino(nitroamino)methyl]amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159945-75-2 CAPLUS

CN L-Prolinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-N-[4-[[imino(nitroamino)methyl]amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 159945-78-5 CAPLUS

CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-N-[4-[[imino(nitroamino)methyl]amino]-1-[oxo[(3-phenylpropyl)amino]acetyl]butyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159945-82-1 CAPLUS

CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-L-prolyl-(3S)-3-amino-6-[[imino(nitroamino)methyl]amino]-2-oxohexanoyl-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159946-33-5 CAPLUS

CN L-Prolineamide, N-(1-oxo-2-propylpentyl)-3-[1-[(phenylmethoxy)methyl]-1H-tetrazol-5-yl]-L-alanyl-N-[4-[[imino(nitroamino)methyl]amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187740-90-5 CAPLUS

CN L-Prolineamide, N-[(2E)-3-(3-methylphenyl)-1-oxo-2-propenyl]-L-.alpha.-aspartyl-N-[(1S)-4-[[imino(nitroamino)methyl]amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




IT 159945-27-4P 159945-28-5P 159945-29-6P  
159945-31-0P 159946-18-6P 159946-39-1P  
187741-29-3P 187741-30-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of antithrombotic sulfonylarginine-contg. keto amide peptides)

RN 159945-27-4 CAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-N-[4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, (S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159945-28-5 CAPLUS

CN L-Prolinamide, N-(4-methyl-1-oxopentyl)-L-.alpha.-aspartyl-N-[4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, (S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159945-29-6 CAPLUS

CN L-Prolinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-N-[4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, (S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159945-31-0 CAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-N-[4-[(aminoiminomethyl)amino]-1-[oxo[(3-phenylpropyl)amino]acetyl]butyl]-, (S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159946-18-6 CAPLUS

CN L-Prolinamide, 3-(1-methyl-1H-tetrazol-5-yl)-N-(1-oxo-2-propylpentyl)-L-

alanyl-N-[4-[[imino(nitroamino)methyl]amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159946-39-1 CAPLUS

CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-L-prolyl-(3S)-3-amino-6-[(aminoiminomethyl)amino]-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187741-29-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-1-[4-(methylsulfonyl)-1-oxo-2-[(1-oxo-2-propylpentyl)amino]butyl]-, [2S-[1(R\*),2R\*(R\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187741-30-6 CAPLUS

CN L-Prolinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 187740-91-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of antithrombotic sulfonylarginine-contg. keto amide peptides)

RN 187740-91-6 CAPLUS

CN L-Prolinamide, N-[(2E)-3-(3-methylphenyl)-1-oxo-2-propenyl]-L-.alpha.-aspartyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



=> d bib 10

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1996:592180 CAPLUS  
DN 125:301554  
TI Poststatin, a new inhibitor of prolyl endopeptidase. V. Endopeptidase  
inhibitory activity of poststatin analogs  
AU Tsuda, Makoto; Muraoka, Yasuhiko; Nagai, Machiko; Aoyagi, Takaaki;  
Takeuchi, Tomio  
CS Inst. Microbial Chem., Tokyo, 141, Japan  
SO Journal of Antibiotics (1996), 49(9), 890-899  
CODEN: JANTAJ; ISSN: 0021-8820  
PB Japan Antibiotics Research Association  
DT Journal  
LA English

=> d bib 11

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1996:157989 CAPLUS  
DN 124:282995  
TI Synthesis, structure, and structure-activity relationships of divalent  
thrombin inhibitors containing an .alpha.-keto-amide transition-state  
mimetic  
AU Krishnan, Raman; Tulinsky, A.; Vlasuk, George P.; Pearson, Daniel; Vallar,  
Pureza; Bergum, Peter; Brunck, Terence K.; Ripka, William C.  
CS Dep. Chemistry, Michigan State Univ., East Lansing, MI, 48824-1322, USA  
SO Protein Science (1996), 5(3), 422-33  
CODEN: PRCIEI; ISSN: 0961-8368  
PB Cambridge University Press  
DT Journal  
LA English

=> d bib 12

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1996:108206 CAPLUS  
DN 124:250214  
TI Comparison of sustained antithrombotic effects of inhibitors of thrombin  
and factor Xa in experimental thrombosis  
AU Biemond, Bart J.; Friederich, Philip W.; Levi, Marcel; Vlasuk, George P.;  
Buller, Harry R.; ten Cate, Jan W.  
CS Center Hemostasis Thrombosis Atherosclerosis and Inflammation Research,  
Academic Medical Center, Amsterdam, 1105 AZ, Neth.  
SO Circulation (1996), 93(1), 153-60

CODEN: CIRCAZ; ISSN: 0009-7322  
 PB American Heart Association  
 DT Journal  
 LA English

=> d bib 13

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1995:733186 CAPLUS  
 DN 123:144645  
 TI Preparation of peptide .alpha.-ketoamide derivatives as antithrombotics and for imaging thrombi.  
 IN Abelman, Matthew Mark; Pearson, Daniel Andrew; Vlasuk, George Phillip; Webb, Thomas Roy  
 PA Corvas International, Inc., USA  
 SO PCT Int. Appl., 191 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9421673	A1	19940929	WO 1994-US3312	19940325 <--
	W: AU, CA, CN, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5656600	A	19970812	US 1993-37574	19930325 <--
	CA 2158989	AA	19940929	CA 1994-2158989	19940325 <--
	AU 9465255	A1	19941011	AU 1994-65255	19940325 <--
	AU 684069	B2	19971204		
	EP 693083	A1	19960124	EP 1994-912880	19940325 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08508259	T2	19960903	JP 1994-521396	19940325 <--
PRAI	US 1993-37574		19930325		
	WO 1994-US3312		19940325		
OS	MARPAT 123:144645				

=> d hitstr 13


YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN  
 IT 166247-65-0P 166247-66-1P 166247-67-2P  
 166247-68-3P 166247-69-4P 166247-70-7P  
 166247-71-8P 166247-72-9P 166247-75-2P  
 166247-76-3P 166247-77-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of peptide .alpha.-ketoamide derivs. as antithrombotics and for imaging thrombi)  
 RN 166247-65-0 CAPLUS  
 CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-




(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-B




PAGE 1-C




PAGE 2-A



PAGE 2-B




PAGE 2-C




RN 166247-66-1 CAPLUS  
 CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginyglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 166247-67-2 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







RN 166247-68-3 CAPLUS

CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B



PAGE 1-C




RN 166247-69-4 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D


—CH(Pr-n)2

RN 166247-70-7 CAPLUS  
 CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D


—CH(Pr-n)<sub>2</sub>

RN 166247-71-8 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D


$$-\text{CH}(\text{Pr}-n)_2$$

RN 166247-72-9 CAPLUS


CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




PAGE 1-D

—CH(Pr-n)<sub>2</sub>


RN 166247-75-2 CAPLUS  
 CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginyglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 166247-76-3 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




PAGE 1-D

—OMe


RN 166247-77-4 CAPLUS  
 CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

